

FREEDOM OF INFORMATION REQUEST

RF23-434

Request:

1. In the past 3 months, how many patients have been treated for urothelial cancer with the following agents?
 - Avelumab
 - Atezolizumab
 - Carboplatin with Gemcitabine
 - Carboplatin single or in any other combination
 - Cisplatin with Gemcitabine
 - Cisplatin single or in any other combination
 - Nivolumab
 - Pembrolizumab
 - Any other systemic anti-cancer therapy
 - Palliative care only
2. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
3. In the past 3 months, how many patients have been treated for colorectal cancer [CRC] with the following agents?
 - Aflibercept
 - Bevacizumab
 - Capecitabine
 - CAPIRI
 - CAPOX (XELOX)
 - Cetuximab in combination with FOLFIRI/FOLFOX
 - Cetuximab not in combination with FOLFIRI or FOLFOX
 - Irinotecan only
 - FOLFIRI
 - FOLFOX
 - Fluorouracil (5FU) only
 - Oxaliplatin only
 - Nivolumab
 - Panitumumab in combination with FOLFIRI/FOLFOX
 - Panitumumab not in combination with FOLFIRI or FOLFOX
 - Pembrolizumab
 - Raltitrexed
 - Ramucirumab
 - Regorafenib
 - Tegafur + Uracil
 - Any other systemic anti-cancer therapy
 - Palliative care only

Response:

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested.



1.

Avelumab	<5 *
Atezolizumab	<5 *
Carboplatin with Gemcitabine	<5*
Carboplatin single or in any other combination	<5 *
Cisplatin with Gemcitabine	8
Cisplatin single or in any other combination	0
Nivolumab	0
Pembrolizumab	0
Other active systemic anti-cancer therapy	0
Palliative care only	Unknown**

2. We have no clinical trials for the treatment of urothelial cancer

3.

Aflibercept	0
Bevacizumab	0
Capecitabine	29
CAPIRI	<5 *
CAPOX (XELOX)	63
Cetuximab in combination with FOLFIRI	18
Cetuximab in combination with FOLFOX	<5 *
Cetuximab not in combination with FOLFIRI or FOLFOX	0
Irinotecan only	5
FOLFIRI	53
FOLFOX	44
Fluorouracil (5FU) only	<5*
Oxaliplatin only	0
Panitumumab in combination with FOLFIRI	12
Panitumumab in combination with FOLFOX	0
Panitumumab not in combination with FOLFIRI or FOLFOX	0
Pembrolizumab	8
Nivolumab	<5 *
Raltitrexed	<5 *
Ramucirumab	0
Regorafenib	0
Tegafur & Uracil	0
Other active systemic anti-cancer therapy	26
Palliative care only	Unknown**



* EKHUFT is unable to confirm the exact number where fewer than five patients are recorded. Given the low number, we consider that disclosure of such information, which constitutes personal data, would contravene the first data protection principle under GDPR. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle, which in our view, would be breached by disclosure. We believe that not disclosing this information is in line with Sections 40(2) and 40(3) of the Freedom of Information Act 2000.

**EKHUFT regret we are unable to answer this question as this data is not recorded in ARIA e-prescribing pharmacy system.

(DATE OF RESPONSE: 18 JULY 2023)

